unlik
major
mammal
uric
acid
final
product
purin
nucleotid
metabol
human
loss
uricas
activ
evolut
loss
uricas
activ
uric
acid
balanc
kidney
lifestyl
chang
eat
habit
associ
recent
high
preval
hyperuricemia
hyperuricemia
caus
uric
acid
crystal
deposit
joint
kidney
consequ
caus
gout
chronic
interstiti
nephriti
moreov
increas
data
suggest
higher
serum
uric
acid
sua
level
may
risk
factor
biomark
renal
cardiovascular
outcom
rang
popul
gener
popul
higher
sua
level
link
develop
newonset
chronic
kidney
diseas
ckd
endstag
renal
diseas
esrd
addit
elev
sua
level
shown
associ
hypertens
diabet
mellitu
dm
metabol
syndrom
coronari
diseas
even
cardiovascular
mortal
associ
sua
level
patient
outcom
seem
complex
kidney
diseas
human
twothird
uric
acid
produc
elimin
urin
therefor
sua
concentr
determin
rate
purin
metabol
effici
renal
clearanc
consequ
elev
sua
level
highli
preval
patient
ckd
make
difficult
determin
causal
coincident
relationship
sua
level
outcom
ckd
popul
compar
gener
popul
previou
studi
effect
sua
level
either
declin
renal
function
cardiovascular
diseas
controversi
find
addit
higher
sua
level
report
associ
increas
neutral
effect
mortal
patient
ckd
regard
patient
esrd
impact
sua
level
mortal
remain
obscur
patient
hemodialysi
hd
jshape
relationship
sua
level
mortal
suggest
wherea
sever
studi
demonstr
hyperuricemia
protect
mortal
cardiovascular
event
periton
dialysi
higher
sua
level
found
harm
residu
renal
function
endotheli
dysfunct
cardiovascular
event
mortal
howev
previou
studi
retrospect
singlecent
trial
singl
measur
small
popul
size
contrast
common
notion
sua
cardiovascular
risk
factor
sua
one
import
antioxid
human
biolog
fluid
thought
sua
contribut
half
antioxid
capac
blood
antioxid
potenti
sua
may
protect
patient
esrd
higher
oxid
stress
individu
preserv
renal
function
therefor
hypothes
lower
sua
level
may
increas
mortal
risk
patient
esrd
prove
hypothesi
explor
associ
sua
level
mortal
patient
esrd
use
nationwid
repres
prospect
esrd
cohort
korea
sua
may
influenc
variou
condit
dialysi
modal
effici
dialysi
nutrit
statu
use
timeaverag
sua
tasua
repres
sua
level
precis
dialysi
patient
enrol
patient
esrd
august
septemb
ongo
cohort
studi
clinic
research
center
end
stage
renal
diseas
crc
esrd
south
korea
crc
esrd
nationwid
multicent
webbas
prospect
cohort
patient
ckd
start
dialysi
investig
regist
clinic
trial
crc
esrd
enrol
total
adult
age
year
esrd
patient
dialysi
center
among
includ
patient
maintain
dialysi
least
month
sua
level
exclud
patient
initi
dialysi
within
month
avail
sua
level
patient
inform
studi
particip
voluntarili
provid
written
consent
studi
approv
institut
review
board
center
clinic
data
collect
form
webbas
medic
questionnair
http
webdbcrcesrdorkr
welltrain
data
coordin
complet
questionnair
item
review
medic
record
conduct
inperson
interview
baselin
inform
time
enrol
includ
age
sex
height
weight
dialysi
durat
total
ktv
primari
renal
diseas
comorbid
dialysi
durat
defin
durat
time
dialysi
initi
date
patient
enrol
date
calcul
month
exclud
medic
effect
sua
level
gather
inform
uricosur
antiuricosur
drug
uricosur
agent
losartan
calcium
channel
block
antihypertens
medic
includ
addit
obtain
concomit
use
aspirin
angiotensin
receptor
blockad
except
losartan
angiotensinogenconvert
enzym
inhibitor
diuret
antiuricosur
agent
time
enrol
check
patient
systol
diastol
blood
pressur
weight
height
bodi
mass
index
bmi
calcul
weight
kg
height
sua
level
may
substanti
affect
one
nutrit
statu
focus
collect
data
associ
patient
nutrit
statu
first
evalu
subject
global
assess
sga
determin
patient
overal
proteinenergi
nutrit
statu
sga
includ
subject
assess
base
patient
histori
weight
chang
dietari
intak
gastrointestin
symptom
function
impair
comorbid
relat
nutrit
need
base
physic
examin
loss
subcutan
fat
muscl
wast
ankl
edema
sacral
edema
ascit
assess
given
score
indic
well
nourish
mild
moder
malnourish
sever
malnourish
second
collect
laboratori
data
plasma
hemoglobin
serum
creatinin
albumin
calcium
phosphoru
highli
sensit
creactiv
protein
hscrp
level
followup
period
sua
level
collect
everi
month
laboratori
clinic
data
averag
sua
obtain
month
calcul
tasua
blood
sampl
collect
prior
dialysi
meal
primari
outcom
allcaus
mortal
enrol
date
mortal
caus
death
report
within
month
event
patient
withdrew
studi
ascertain
mortal
data
statist
korea
combin
data
accord
uniqu
identif
number
held
korean
provid
inform
consent
assum
patient
report
death
meet
primari
outcom
time
data
closeout
addit
caus
death
divid
categori
cardiac
vascular
infect
liver
diseas
gastrointestin
metabol
endocrin
caus
caus
death
collect
die
compar
baselin
characterist
accord
tasua
level
particip
stratifi
group
tasua
level
follow
refer
mgdl
differ
among
tasua
group
test
use
test
categor
variabl
analysi
varianc
test
continu
variabl
assess
relationship
tasua
level
demograph
clinic
data
univari
multivari
linear
regress
analys
perform
variabl
show
signific
associ
p
univari
analysi
age
sex
dialysi
type
bmi
sga
albumin
level
tasua
diabet
consider
theoret
relev
total
ktv
calcium
level
phosphoru
level
hypertens
gout
uricosur
drug
antiuricosur
drug
enter
multivari
stepwis
linear
regress
model
covari
colinear
exclud
multivari
analys
explor
associ
tasua
level
mortal
patient
dialysi
curv
plot
accord
tasua
group
also
fit
restrict
cubic
spline
function
analys
restratifi
particip
group
tasua
level
tasua
mgdl
vs
mgdl
surviv
differ
compar
logrank
test
calcul
rel
risk
death
hazard
ratio
hr
confid
interv
ci
obtain
cox
proport
hazard
model
proport
hazard
assumpt
cox
model
test
log
minu
log
plot
factor
show
signific
associ
p
univari
analysi
import
clinic
concern
enter
timedepend
multivari
cox
regress
analysi
variabl
select
perform
use
forward
condit
method
sinc
associ
tasua
mgdl
mortal
patient
dialysi
may
featur
malnutrit
dissect
relationship
accord
sga
albumin
level
bmi
also
perform
subgroup
analys
accord
age
paramet
proven
affect
sua
level
independ
statist
analys
perform
use
spss
version
window
spss
inc
chicago
il
stata
version
statacorp
lp
colleg
station
tx
statist
signific
defin
p
among
total
patient
crcesrd
cohort
exclud
incid
hemodialysi
patient
patient
without
avail
sua
level
therefor
patient
includ
final
analysi
fig
among
women
n
men
n
mean
age
year
median
followup
month
fig
show
tasua
level
distribut
accord
sex
tasua
level
distribut
much
differ
men
women
although
tasua
level
slightli
higher
men
women
mgdl
vs
mgdl
p
tabl
present
differ
baselin
characterist
tasua
level
tasua
level
decreas
particip
older
women
patient
lower
tasua
level
tend
higher
proport
malnourish
lowest
tasua
group
vs
highest
tasua
group
p
addit
lower
bmi
serum
phosphoru
triglycerid
lowdens
lipoprotein
cholesterol
total
protein
albumin
level
patient
higher
tasua
level
howev
dialysi
effici
better
lower
tasua
group
higher
tasua
group
p
although
insignific
tasua
level
decreas
proport
diabet
increas
wherea
gout
decreas
comorbid
condit
p
analyz
baselin
characterist
divid
dialysi
type
baselin
characterist
show
similar
trend
accord
sua
group
hd
pd
patient
supplementari
tabl
next
explor
baselin
paramet
affect
tasua
level
popul
tabl
summar
result
tasua
level
signific
posit
correl
nutrit
factor
bmi
regress
coeffici
b
p
sga
b
p
serum
phosphoru
level
b
p
albumin
level
b
p
level
hscrp
gout
show
relationship
regard
dialysi
type
patient
periton
dialysi
pd
associ
lower
tasua
level
antiuricosur
drug
significantli
associ
tasua
b
p
uricosur
drug
b
p
interestingli
invers
associ
tasua
level
dm
b
p
make
adjust
found
pd
lower
bmi
lower
albumin
level
lower
serum
phosphoru
level
combin
dm
significantli
associ
lower
sua
level
followup
period
patient
die
allcaus
mortal
rate
higher
patient
pd
hd
vs
p
figur
illustr
categor
mortal
rate
highest
tasua
group
similar
mortal
rate
middl
tasua
group
howev
lowest
tasua
group
steepli
elev
mortal
rate
compar
tasua
group
figur
show
nonlinear
mortal
risk
accord
tasua
level
adjust
clinic
covari
age
sex
dialysi
type
sbp
bmi
diabet
albumin
level
sga
term
nonlinear
spline
curv
overal
ushap
associ
tasua
level
adjust
log
hr
differ
wide
rang
ci
mortal
risk
higher
tasua
level
increas
mortal
risk
promin
lower
tasua
level
narrow
ci
rang
moreov
associ
obviou
tasua
level
mgdl
term
hr
ci
subsequ
perform
surviv
analys
stratifi
tasua
group
tasua
mgdl
tasua
mgdl
figur
show
surviv
curv
obtain
use
method
patient
tasua
mgdl
significantli
higher
mortal
rate
compar
tasua
mgdl
log
rank
p
similar
trend
observ
divid
hd
pd
group
fig
explor
effect
tasua
level
allcaus
mortal
perform
cox
regress
analys
tabl
summar
result
univari
multivari
analys
univari
analysi
found
tasua
mgdl
significantli
associ
allcaus
mortal
unadjust
hr
ci
p
moreov
tasua
mgdl
independ
risk
factor
allcaus
mortal
even
adjust
clinic
covari
age
dialysi
type
total
ktv
bmi
sga
serum
calcium
phosphoru
albumin
tasua
dm
hypertens
gout
uricosur
drug
antiuricosur
drug
adjust
hr
ci
p
sinc
associ
sua
mgdl
mortal
patient
dialysi
may
featur
malnutrit
dissect
relationship
accord
sga
albumin
level
bmi
also
perform
subgroup
analys
accord
age
sex
dialysi
type
paramet
proven
affect
sua
level
independ
describ
tabl
figur
summar
result
signific
interact
subgroup
except
dm
harm
effect
tasua
mgdl
level
allcaus
mortal
promin
age
year
group
adjust
hr
ci
p
p
interact
patient
hd
treatment
adjust
hr
ci
p
p
interact
overweight
bmi
adjust
hr
ci
p
p
interact
normoalbuminem
adjust
hr
ci
p
p
interact
wellnourish
adjust
hr
ci
p
p
interact
patient
dm
adjust
hr
ci
p
p
interact
harm
effect
tasua
similar
women
adjust
hr
ci
p
men
adjust
hr
ci
p
p
interact
tabl
show
caus
death
accord
tasua
level
overal
common
caus
death
infect
n
cardiogen
caus
n
distribut
caus
death
differ
accord
tasua
level
studi
explor
relationship
tasua
level
allcaus
mortal
mainten
dialysi
patient
sua
level
easili
affect
diet
effici
dialysi
drug
notabl
use
tasua
blood
sampl
collect
prior
dialysi
meal
instead
singlebaselin
measur
sua
found
distribut
tasua
level
much
differ
accord
sex
much
gener
popul
expect
tasua
level
associ
patient
nutrit
statu
also
demonstr
lower
tasua
level
especi
lowest
mgdl
among
dialysi
group
independ
associ
allcaus
mortal
median
followup
month
relationship
remain
signific
consid
nutrit
statu
paramet
associ
tasua
level
refer
rang
sua
typic
mgdl
men
mgdl
women
sex
differ
well
describ
previou
studi
perform
gener
popul
patient
dialysi
limit
data
sex
differ
sua
level
distribut
previou
studi
shown
sua
level
men
higher
women
mgdl
studi
differ
mgdl
signific
reason
differ
cohort
remain
uncertain
advanc
age
menopaus
statu
impair
renal
uric
acid
excret
state
sex
hormon
dysfunct
urem
statu
may
affect
sua
metabol
although
studi
warrant
clarifi
smaller
sex
differ
sua
level
mechan
relationship
sua
level
mortal
esrd
explor
hd
cohort
pd
cohort
result
divers
sever
studi
show
low
sua
level
may
harm
mortal
wherea
other
insist
hyperuricemia
increas
mortal
one
studi
even
report
prognost
valu
sua
mortal
weak
may
confound
tradit
cardiovascular
risk
factor
uremiarel
factor
heterogen
may
deriv
mani
confound
affect
sua
level
patient
dialysi
first
sua
consid
one
nutrit
factor
patient
dialysi
recent
studi
clarifi
associ
sua
level
nutrit
statu
patient
hd
therefor
nutrit
marker
fine
adjust
demonstr
independ
prognost
valu
sua
mortal
patient
esrd
prospect
studi
consid
possibl
nutrit
factor
includ
sga
bmi
serum
albumin
phosphoru
level
bmi
paradox
variabl
mortal
patient
esrd
hypoalbuminemia
also
well
establish
potent
independ
risk
factor
morbid
mortal
patient
dialysi
asid
laboratori
marker
also
consid
sga
repres
overal
concept
nutrit
factor
subject
recent
weight
chang
dietari
intak
gastrointestin
symptom
loss
subcutan
fat
sign
muscl
wast
patient
esrd
sga
independ
predictor
mortal
larg
longitudin
cohort
studi
subgroup
analys
independ
role
lowest
sua
level
elev
mortal
promin
wellnourish
sga
higher
bmi
higher
serum
albumin
level
group
counterpart
impli
sua
level
simpl
marker
reflect
nutrit
statu
patient
chronic
dialysi
anoth
import
issu
address
hyper
hypouricemia
associ
increas
mortal
two
previou
studi
patient
pd
illustr
common
concept
show
hyperuricemia
associ
increas
allcaus
especi
cardiovascular
mortal
howev
studi
enrol
patient
rel
young
age
fewer
comorbid
compar
cohort
studi
limit
includ
small
sampl
size
short
followup
durat
studi
particip
observ
prospect
nation
distribut
multicent
therefor
repres
realworld
patient
chronic
dialysi
studi
demonstr
lower
tasua
level
increas
allcaus
mortal
patient
chronic
dialysi
sua
power
scaveng
oxygenfre
radic
act
one
import
antioxid
human
biolog
fluid
enough
evid
lower
sua
level
associ
inflammatori
degen
diseas
patient
dialysi
found
total
antioxid
capac
correl
sua
level
due
primarili
higher
level
sua
therefor
possibl
lower
sua
level
result
reduc
total
antioxid
capac
patient
dialysi
although
investig
warrant
clarifi
precis
mechan
strength
studi
follow
prospect
cohort
studi
larg
number
patient
treat
pd
hd
multipl
center
complet
detail
assess
adjust
nutrit
metabol
risk
factor
drug
import
confound
sua
level
consid
dialysisrel
factor
may
elimin
sua
patient
limit
absent
renal
function
consequ
suggest
import
underestim
role
sua
antioxid
patient
dialysi
use
tasua
instead
singl
sua
measur
minim
fluctuat
effect
sua
howev
sever
limit
note
first
could
obtain
partial
inform
medic
may
chang
sua
level
sinc
studi
prospect
cohort
design
obtain
inform
time
studi
design
although
could
gather
medic
gout
treatment
could
adjust
gout
histori
uricosur
agent
antiuricosur
agent
even
adjust
gout
drug
affect
sua
level
tasua
mgdl
independ
risk
factor
allcaus
mortal
second
also
could
consid
antioxid
paramet
may
provid
one
relationship
sua
antioxid
capac
among
usual
laboratori
test
total
bilirubin
gammaglutamyltransferas
ggt
consid
marker
oxid
stress
collabor
alreadi
demonstr
high
serum
ggt
level
independ
risk
factor
allcaus
mortal
pd
patient
use
cohort
unfortun
serum
ggt
level
collect
patient
cohort
could
includ
serum
ggt
level
covari
regress
analysi
furthermor
total
bilirubin
level
collect
prospect
cohort
translat
research
may
warrant
demonstr
precis
antioxid
effect
sua
mortal
conclus
studi
demonstr
impact
sua
surviv
esrd
patient
tasua
mgdl
associ
higher
mortal
patient
associ
promin
age
overweight
normoalbuminem
wellnourish
diabet
patient
causal
relationship
still
obscur
research
warrant
clarifi
precis
mechan
author
acknowledg
investig
cohort
studi
clinic
research
center
end
stage
renal
diseas
south
korea
